Clinical trial
Antipsychotic Discontinuation in Alzheimer's Disease
NCT00417482 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00417482 |
|---|---|
| Title | Antipsychotic Discontinuation in Alzheimer's Disease |
| Official title | Antipsychotic Discontinuation in Alzheimer's Disease |
| Acronym | ADAD |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | National Institute on Aging (NIA) NIH Columbia University |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Psychotic Disorders, Agitation, Aggression |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 180 |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Jan 1, 2007 |
| Last update posted | Apr 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: